Weifa ASA is pleased to announce the launch of Ibux® 200 mg soft capsules, a line extension to the already well established Ibux® range.
Ibux® is as per today the 4th most sold OTC brand in Norway. It is part of the MNOK 92 LTM NSAIDS segment, where it is the number one brand with a market share of 73%.
“We are strengthening our product portfolio in the second largest segment within pain”, says CEO Kathrine Gamborg Andreassen. “The launch of Ibux® 200 soft capsules is set to strengthen its current position as market leader in the segment.”
The launch will be supported by a solid communications campaign towards consumers.
Ibux® 200 mg soft capsules comes in addition to the 400 mg soft capsules, 200 mg tablets and 400 mg tablets, 20 mg suspension, as well as the Ibux® range of gels.
The product represents a new opportunity in that the innovative soft capsules can now be used by children down to 6 years of age. It contains ibuprofen and is indicated for short term treatment for mild to moderate pain and fever. The soft capsules are small in size and have no taste. Its content is already dissolved and is therefore quickly absorbed.
It will be available through pharmacy and grocery channels from October 2016.
For further information, please contact:
Kathrine Gamborg Andreassen
+47 95 17 86 80, email@example.com
+47 98 20 63 55, firstname.lastname@example.org
Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no
Ref: 1: Farmastat September, 2016.